Effector Therapeutics Inc Financials
This page shows Effector Therapeutics Inc (EFTR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
eFFECTOR’s economics are still driven by research spending, with cash burn funded externally rather than by recurring revenue.
Across the last two valid years, operating cash burn stayed in the same range, moving from-$25.9M to-$29.6M , which suggests the underlying cost base did not meaningfully reset despite a smaller asset base. Cash still rose to$14.9M because financing and asset-related inflows outweighed that burn, so the higher cash balance did not reflect a healthier core engine and short-term obligations still exceeded current assets.
In FY2022, this remained a research-funded enterprise, not a scaled seller: R&D ran at about 6.6x revenue. R&D also stayed above SG&A in FY2023, meaning the cost base is still being set more by program development than by commercial support, and product income is not yet carrying operations.
Cash consumption is almost entirely operating: FY2023 free cash flow of
Financial Health Signals
We are recalculating Effector Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Effector Therapeutics Inc scores -17.99, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($612K) relative to total liabilities ($26.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Effector Therapeutics Inc passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Effector Therapeutics Inc generates $0.83 in operating cash flow (-$29.6M OCF vs -$35.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Effector Therapeutics Inc earns $-11.6 in operating income for every $1 of interest expense (-$33.8M vs $2.9M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Effector Therapeutics Inc generated $0 in revenue in fiscal year 2023. This represents a decrease of 100.0% from the prior year.
Effector Therapeutics Inc's EBITDA was -$33.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 4.3% from the prior year.
Effector Therapeutics Inc reported -$35.8M in net income in fiscal year 2023. This represents a decrease of 58.0% from the prior year.
Effector Therapeutics Inc earned $-16.37 per diluted share (EPS) in fiscal year 2023. This represents a decrease of 19.0% from the prior year.
Cash & Balance Sheet
Effector Therapeutics Inc generated -$29.6M in free cash flow in fiscal year 2023, representing cash available after capex. This represents a decrease of 13.6% from the prior year.
Effector Therapeutics Inc held $14.9M in cash against $20.0M in long-term debt as of fiscal year 2023.
Effector Therapeutics Inc had 3M shares outstanding in fiscal year 2023. This represents an increase of 78.9% from the prior year.
Margins & Returns
Capital Allocation
Effector Therapeutics Inc invested $22.9M in research and development in fiscal year 2023. This represents a decrease of 1.7% from the prior year.
Effector Therapeutics Inc invested $97K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents a decrease of 49.5% from the prior year.
EFTR Income Statement
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | N/A | $0 | $0 | $0 | N/A | $867K-56.9% | $2.0M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.3M | N/A | $5.4M+9.7% | $4.9M-26.1% | $6.6M | N/A | $6.6M-4.1% | $6.9M |
| SG&A Expenses | $3.1M | N/A | $2.5M-15.9% | $3.0M+1.6% | $2.9M | N/A | $3.5M+17.3% | $3.0M |
| Operating Income | -$8.4M | N/A | -$7.9M0.0% | -$7.9M+17.6% | -$9.5M | N/A | -$9.3M-17.4% | -$7.9M |
| Interest Expense | $749K | N/A | $750K+3.9% | $722K+4.8% | $689K | N/A | $570K+12.9% | $505K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$8.8M | N/A | -$8.3M+0.7% | -$8.4M+16.5% | -$10.0M | N/A | -$9.6M-38.2% | -$6.9M |
| EPS (Diluted) | $-2.16 | N/A | $-0.13+23.5% | $-0.17+97.1% | $-5.96 | N/A | $-0.23-35.3% | $-0.17 |
EFTR Balance Sheet
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $27.1M+32.1% | $20.5M+1.9% | $20.2M-25.0% | $26.9M+22.6% | $21.9M-24.6% | $29.1M-20.7% | $36.7M-15.7% | $43.5M |
| Current Assets | $26.3M+32.3% | $19.8M+2.9% | $19.3M-25.8% | $26.0M+24.3% | $20.9M-25.4% | $28.0M-21.1% | $35.5M-16.0% | $42.3M |
| Cash & Equivalents | $15.5M+4.3% | $14.9M+176.2% | $5.4M-63.4% | $14.7M+42.7% | $10.3M+18.4% | $8.7M-26.8% | $11.9M-27.2% | $16.4M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $26.3M-0.1% | $26.3M+9.2% | $24.1M-0.8% | $24.3M-9.1% | $26.7M+6.2% | $25.2M+0.4% | $25.1M+5.2% | $23.8M |
| Current Liabilities | $25.6M-0.9% | $25.8M+9.4% | $23.6M-0.7% | $23.8M-10.9% | $26.7M+6.3% | $25.1M+0.4% | $25.0M+5.9% | $23.6M |
| Long-Term Debt | $19.4M-2.8% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M0.0% | $20.0M |
| Total Equity | $827K+114.3% | -$5.8M-46.1% | -$4.0M-254.0% | $2.6M+153.5% | -$4.8M-223.5% | $3.9M-66.3% | $11.6M-41.1% | $19.6M |
| Retained Earnings | -$188.2M-4.9% | -$179.4M-5.4% | -$170.2M-5.1% | -$161.9M-5.4% | -$153.6M-7.0% | -$143.6M-6.9% | -$134.3M-7.7% | -$124.7M |
EFTR Cash Flow Statement
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M-30.8% | -$5.6M+28.2% | -$7.8M+9.7% | -$8.6M-12.5% | -$7.6M-12.6% | -$6.8M+17.2% | -$8.2M-84.4% | -$4.4M |
| Capital Expenditures | $0-100.0% | $54K | N/A | N/A | $13K0.0% | $13K | N/A | N/A |
| Free Cash Flow | -$7.3M-29.5% | -$5.6M | N/A | N/A | -$7.7M-12.6% | -$6.8M | N/A | N/A |
| Investing Cash Flow | -$6.3M-170.7% | $8.9M+567.2% | -$1.9M-21.7% | -$1.6M-117.4% | $9.0M+149.2% | $3.6M0.0% | $3.6M+14.3% | $3.2M |
| Financing Cash Flow | $14.2M+133.0% | $6.1M+1686.3% | $342K-97.7% | $14.6M+6772.6% | $212K+673.0% | -$37K-133.3% | $111K+364.3% | -$42K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EFTR Financial Ratios
| Metric | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1067.0%-675.1pp | -391.9% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | -1102.5%-758.7pp | -343.9% |
| Return on Equity | -1068.2% | N/A | N/A | -324.8% | N/A | N/A | -82.7%-47.4pp | -35.2% |
| Return on Assets | -32.6% | N/A | -41.2%-10.1pp | -31.1%+14.6pp | -45.7% | N/A | -26.1%-10.2pp | -15.9% |
| Current Ratio | 1.03+0.3 | 0.77-0.0 | 0.82-0.3 | 1.09+0.3 | 0.78-0.3 | 1.12-0.3 | 1.42-0.4 | 1.79 |
| Debt-to-Equity | 23.51+27.0 | -3.45+1.6 | -5.04-12.8 | 7.77+11.9 | -4.16-9.3 | 5.13+3.4 | 1.73+0.7 | 1.02 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$5.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.77), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Effector Therapeutics Inc's annual revenue?
Effector Therapeutics Inc (EFTR) reported $0 in total revenue for fiscal year 2023. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Effector Therapeutics Inc's revenue growing?
Effector Therapeutics Inc (EFTR) revenue declined by 100% year-over-year, from $3.6M to $0 in fiscal year 2023.
Is Effector Therapeutics Inc profitable?
No, Effector Therapeutics Inc (EFTR) reported a net income of -$35.8M in fiscal year 2023.
What is Effector Therapeutics Inc's EBITDA?
Effector Therapeutics Inc (EFTR) had EBITDA of -$33.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Effector Therapeutics Inc have?
As of fiscal year 2023, Effector Therapeutics Inc (EFTR) had $14.9M in cash and equivalents against $20.0M in long-term debt.
What is Effector Therapeutics Inc's free cash flow?
Effector Therapeutics Inc (EFTR) generated -$29.6M in free cash flow during fiscal year 2023. This represents a -13.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Effector Therapeutics Inc's operating cash flow?
Effector Therapeutics Inc (EFTR) generated -$29.6M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.
What are Effector Therapeutics Inc's total assets?
Effector Therapeutics Inc (EFTR) had $20.5M in total assets as of fiscal year 2023, including both current and long-term assets.
What are Effector Therapeutics Inc's capital expenditures?
Effector Therapeutics Inc (EFTR) invested $97K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
How much does Effector Therapeutics Inc spend on research and development?
Effector Therapeutics Inc (EFTR) invested $22.9M in research and development during fiscal year 2023.
What is Effector Therapeutics Inc's current ratio?
Effector Therapeutics Inc (EFTR) had a current ratio of 0.77 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is Effector Therapeutics Inc's debt-to-equity ratio?
Effector Therapeutics Inc (EFTR) had a debt-to-equity ratio of -3.45 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Effector Therapeutics Inc's return on assets (ROA)?
Effector Therapeutics Inc (EFTR) had a return on assets of -174.3% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is Effector Therapeutics Inc's cash runway?
Based on fiscal year 2023 data, Effector Therapeutics Inc (EFTR) had $14.9M in cash against an annual operating cash burn of $29.6M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Effector Therapeutics Inc's debt-to-equity ratio negative or unusual?
Effector Therapeutics Inc (EFTR) has negative shareholder equity of -$5.8M as of fiscal year 2023, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Effector Therapeutics Inc's Altman Z-Score?
Effector Therapeutics Inc (EFTR) has an Altman Z-Score of -17.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Effector Therapeutics Inc's Piotroski F-Score?
Effector Therapeutics Inc (EFTR) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Effector Therapeutics Inc's earnings high quality?
Effector Therapeutics Inc (EFTR) has an earnings quality ratio of 0.83x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Effector Therapeutics Inc cover its interest payments?
Effector Therapeutics Inc (EFTR) has an interest coverage ratio of -11.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.